Research presented at the EADV Congress 2025 indicates that psoriasis patients undergoing biologic treatment have a 27% reduced risk of age-related macular degeneration (AMD) compared to those using only topical corticosteroids. A retrospective study involving 22,901 patients over 55 reveals an association between psoriasis and higher AMD risk, with psoriasis patients showing a 56% increased risk compared to those with major depressive disorder. The findings suggest that biologic therapies may offer protective effects against AMD, highlighting the need for regular eye examinations in psoriasis patients.

Source: EADV Congress 2025